Sai Parenterals Ltd
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
- Market Cap ₹ 2,142 Cr.
- Current Price ₹ 485
- High / Low ₹ 526 / 400
- Stock P/E 207
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 13.9 %
- ROE 12.2 %
- Face Value ₹ 5.00
Pros
Cons
- Company has a low return on equity of 12.9% over last 3 years.
- Company has high debtors of 254 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 97 | 114 | 124 | |
| 79 | 92 | 97 | |
| Operating Profit | 18 | 21 | 27 |
| OPM % | 18% | 19% | 22% |
| 0 | 1 | 0 | |
| Interest | 5 | 6 | 7 |
| Depreciation | 6 | 6 | 5 |
| Profit before tax | 7 | 10 | 14 |
| Tax % | 37% | 30% | 28% |
| 5 | 7 | 10 | |
| EPS in Rs | 6.43 | 5.40 | 3.88 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 7 | 13 | 13 |
| Reserves | 24 | 65 | 78 |
| 69 | 71 | 72 | |
| 34 | 45 | 52 | |
| Total Liabilities | 134 | 194 | 215 |
| 44 | 41 | 40 | |
| CWIP | 2 | 0 | 0 |
| Investments | 0 | 28 | 28 |
| 88 | 124 | 146 | |
| Total Assets | 134 | 194 | 215 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| -21 | -4 | 10 | |
| -17 | -32 | -4 | |
| 30 | 36 | -6 | |
| Net Cash Flow | -8 | -1 | -0 |
| Free Cash Flow | -38 | -7 | 6 |
| CFO/OP | -103% | -6% | 51% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 231 | 272 | 254 |
| Inventory Days | 83 | 97 | 130 |
| Days Payable | 140 | 156 | 160 |
| Cash Conversion Cycle | 174 | 213 | 224 |
| Working Capital Days | 27 | 70 | 59 |
| ROCE % | 13% | 14% |
Documents
Announcements
-
Results-Delay in Financial Results
2d - Sai Parenterals delays results submission to 15 May 2026; audited FY26 results due by 30 May 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting
20 Apr - Board approved up to AUD 1.75 million loan to Sai Singapore Pte. Ltd. on April 20, 2026.
-
Board Meeting Intimation for INTIMATION OF BOARD MEETING WHICH IS PROPOSED TO BE HELD ON 20TH OF APRIL 2026
14 Apr - Board meeting on April 20, 2026 to consider investing in or lending to Noumed Pharmaceuticals Pty Limited.
-
Closure of Trading Window
6 Apr - Trading window closed from April 2, 2026 for Q3 and FY26 results board meeting.
-
Intimation Under Regulation 30(5) Of SEBI
6 Apr - Sai Parenterals appointed three KMPs as authorised persons under Regulation 30(5).
Annual reports
No data available.
Business Profile[1][2]
Sai Parenteral is a diversified pharmaceutical formulations company engaged in R&D, manufacturing, and commercialization of products across both domestic and international markets. Over time, the company has evolved from being a parenteral-focused player into a full-fledged diversified formulations platform, significantly reducing its dependency on injectables in the process.